Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00458_DB00472_nanopub.RAqogGomk5gg5X50-k7jvbPYLjCJM861RTdcq_jc4RGcQ#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00458_DB00472 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00458_DB00472 label "DDI between Imipramine and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00458_DB00472]" assertion.
- drugbank_resource:DB00458_DB00472 identifier "drugbank_resource:DB00458_DB00472" assertion.
- drugbank_resource:DB00458_DB00472 title "DDI between Imipramine and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00472 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00458_DB00472 assertion.
- drugbank:DB00458 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00458_DB00472 assertion.